Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for the Treatment of Cervical Intraepithelial Neoplasia
NCT04266275Phase 2Not yet recruiting
- Start
- Apr 2027
- Primary completion
- Oct 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection comparing Curcumin Arm with Placebo Arm (2 arms). Primary endpoint: Human Papillomavirus Clearance at 6 months. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
curcumin
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT04266275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266275.